| Trial ID: | L2095 |
| Source ID: | NCT06329882
|
| Associated Drug: |
Sitagliptin 100mg
|
| Title: |
Doxycycline in Type II Diabetes
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Sitagliptin 100mg|DRUG: Doxycyclin
|
| Outcome Measures: |
Primary: Change in glycemic profile, measurement of fasting blood glucose (FBG), 3 months|Change in glycemic profile, measurement of glycated hemoglobin, 3 months |
|
| Sponsor/Collaborators: |
Sponsor: Mostafa Bahaa
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2024-03-30
|
| Completion Date: |
2026-04-20
|
| Results First Posted: |
|
| Last Update Posted: |
2025-04-04
|
| Locations: |
Tanta Unuversity, Tanta, 31527, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT06329882
|
